"Celldex Reports Progress Against Brain Cancer
Researchers haven’t had much to brag about in recent years for treating a type of primary brain tumor, known as glioblastoma multiforme. Hampton, NJ-based Celldex Therapeutics released further data from its immunotherapy rindopepimut (Rintega), from a clinical trial that randomly assigned 73 patients to get the new drug in addition to the standard treatment– Genentech’s bevacizumab (Avastin)–or the standard treatment alone. About 28% were alive and with tumors that hadn’t worsened after six months of treatment compared with 16% who did that well on standard therapy. After 18 months of follow-up, 30% of patients on the Celldex drug were alive compared with 15% of those in the control group. The company is discussing whether the data are compelling enough to seek accelerated approval from the FDA, according to this report by TheStreet's Adam Feuerstein."